Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Onabotulinumtoxina · Botox, Botox Cosmetic

Recombinant protein · Inhibitor of SNAP-25 · developed by Allergan

Approved FDA, Dec 1991
ABBV Developer
2 Registered trials

What is Onabotulinumtoxina?

Onabotulinumtoxina (BOTOX) is a botulinum neurotoxin type A that enters nerve terminals and cleaves SNAP-25, blocking acetylcholine release and causing localized partial chemical denervation of muscle or reduced sweat gland activity. It is used in neurologic, urologic, musculoskeletal, ophthalmic and cosmetic indications involving muscle overactivity or excess sweating.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Botox, Botox Cosmetic, BOTOX
Drug type
Recombinant protein
Targets
SNAP-25
Mechanism
Inhibitor of SNAP-25
Pathways
acetylcholine release inhibition at neuromuscular junction, cholinergic neurotransmission in autonomic nerve terminals
Therapy area
Dermatology, Musculoskeletal, Neurology, Ophthalmology, Renal & urology
Developer
Allergan (ABBV)
FDA status
Approved as Botox, Botox Cosmetic (December 9, 1991), BLA103000 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 2, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06068855 Phase 3 Masseter Muscle Prominence Completed ABBV
NCT07871513 Phase 2 Upper Facial Lines Recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glabellar LinesUpper Facial Lines

More from Allergan

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Onabotulinumtoxina

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.